Unfortunately, the original version of this article [1] contained errors. The errors have been addressed point by point in full detail below.
Correction 1 Regarding primary efficacy endpoint (symptomatic recurrent VTE) and composite outcome of symptomatic recurrent VTE or asymptomatic deterioration in rivaroxaban group, we've found "1.3 %" (1 patient in 78 population), is correct instead of current "1.4 %", it should be replaced in Page 1, Line 16 in the abstract section, and on the right side of Page 5, Line 1. However, it is not necessary to replace the number "1.4%" in Table 3 because it was calculated by another definition. Therefore we also would like to add a description of the excluded population, "patients assessed as "not evaluable" were excluded from these analyses", in footnotes of Table 2  and Table 3 .
Correction 2 Due to changes made in correction 1, we need to recalculate absolute risk differences and 95 % Confidence Interval of composite outcome of symptomatic recurrent VTE or asymptomatic deterioration, and we consider these numbers also need to be corrected. And to clarify this "difference" means rivaroxaban reduces risk compared to control, we would like to choose the absolute risk "reduction" instead of "difference". Absolute risk "reduction" was 4.0 % compared to control, and 95 % CI was (-2.9 to 24.0). We should change these numbers in Page 1, Line 17 in the abstract section, in the right side of Page 5, Line 2 and in the right side of Page 6, Line 6.
Correction 3
There was a trivial miscalculation of percentage in the Table 3 . Rivaroxaban combined result in DVT and PE patients, 2 patients in 71 was evaluated as "unchanged", therefore percentage is "2.8 %" instead of current "2.9 %". The lower limit of the confidence interval (i.e. -3.4 %) around the absolute difference in the composite efficacy outcome suggests that an important deterioration in treatment effect can be excluded for rivaroxaban.
The lower limit of the confidence interval (i.e. -2.9 %) around the absolute reduction in the composite efficacy outcome suggests that an important deterioration in treatment effect can be excluded for rivaroxaban.
